Prometrium Alcohol Interaction Profile

What the FDA Label Says About Prometrium and Alcohol

The Prometrium prescribing information, reviewed by the FDA, states directly that alcohol and other CNS-depressant drugs can potentiate the drowsiness seen with micronized progesterone. Patients are advised not to drive or operate machinery after taking Prometrium, a caution that becomes stronger when alcohol is added to the picture. The label also notes that a single 200 mg bedtime dose produced measurable psychomotor impairment in clinical studies compared with placebo. [1]

Why the Label Specifically Calls Out Alcohol

Oral micronized progesterone is absorbed in an oily matrix (peanut oil), which gives it high bioavailability relative to crystalline progesterone but also exposes the CNS to progesterone metabolites, particularly allopregnanolone (3α-hydroxy-5α-pregnan-20-one), at pharmacologically active concentrations. [2]

Allopregnanolone is a positive allosteric modulator of GABA-A receptors, the same receptor target through which ethanol exerts much of its sedating and anxiolytic effect. When both agents occupy the GABA-A complex simultaneously, the result is an additive, and potentially synergistic, increase in chloride channel opening frequency. That is the pharmacological basis for the label warning.

The Bedtime-Dosing Recommendation Is Not Coincidental

Prescribers routinely recommend the 200 mg dose at bedtime precisely because of this sedating property. A 2011 randomized trial by Schüssler et al. (N=40 postmenopausal women) found that 300 mg of oral micronized progesterone significantly increased NREM sleep duration and subjective sleep quality scores compared with placebo, a finding consistent with GABA-A modulation. [3] Bedtime dosing converts a side effect into a benefit, but it does not eliminate the interaction window with alcohol consumed in the hours before sleep.

Pharmacokinetics: How Overlapping Drug and Alcohol Peaks Create Risk

Oral Prometrium reaches peak serum progesterone concentrations (Cmax) within approximately 2 to 3 hours of ingestion. The allopregnanolone metabolite tracks closely with the progesterone curve. [2] A standard alcoholic drink (14 g ethanol) reaches peak blood-alcohol concentration within 30 to 90 minutes of consumption, with a half-life of roughly 1 hour depending on body weight and food intake.

The practical implication: a woman who takes her 200 mg Prometrium at 9 PM and has two glasses of wine between 7 to 8 PM will have overlapping CNS-active concentrations of both agents for 2 to 4 hours during early sleep. Falls, confusion on waking to urinate, and next-morning grogginess are the most commonly reported clinical consequences.

CYP Enzyme Competition

Both ethanol oxidation and progesterone metabolism draw on overlapping cytochrome P450 pathways. CYP2C19 metabolizes progesterone, and chronic alcohol use both induces and can eventually inhibit CYP2C19 activity, depending on drinking pattern. [4] Acute ethanol ingestion tends to inhibit CYP2C19 transiently, which may slow progesterone clearance and extend the duration of peak allopregnanolone exposure.

CYP3A4 is the dominant route for progesterone catabolism. Moderate chronic alcohol consumption has been shown to induce CYP3A4, which could theoretically lower steady-state progesterone levels in regular drinkers on HRT, although this effect has not been specifically quantified for Prometrium in a dedicated clinical pharmacokinetic trial.

Alcohol Also Elevates Endogenous Estrogen

A point less often discussed in drug-interaction reviews: alcohol inhibits hepatic first-pass estrogen metabolism, raising circulating estradiol levels by 10 to 30% after moderate intake. [5] In women taking combined estrogen-progesterone HRT regimens, this raises the overall hormonal exposure above the prescribed dose. The clinical relevance for breast-cancer risk is an area of active research, and the WHI Observational Study flagged alcohol as an independent modifier of breast-cancer risk in postmenopausal HRT users.

CNS Depression: Clinical Evidence Beyond the Label

The sedative properties of oral micronized progesterone are not theoretical. A crossover pharmacodynamic study by Freeman et al. Published in Psychoneuroendocrinology administered 300 mg oral micronized progesterone to healthy women and documented statistically significant increases in sedation scores (P<0.01 vs. Placebo) and reductions in choice reaction time within 2 hours of dosing. [6]

What Happens When Alcohol Is Added

No published randomized trial has deliberately combined therapeutic-dose Prometrium with a controlled alcohol dose in a clinical setting (an ethical and regulatory hurdle). The interaction is therefore characterized as a class-effect pharmacodynamic interaction, consistent with how the FDA handles all progesterone formulations and CNS-depressant combinations.

Reported clinical presentations from pharmacovigilance data and prescriber experience include:

• Dizziness severe enough to require assistance standing
• Falls, particularly in older postmenopausal women
• Anterograde memory gaps the following morning
• Excessive sedation persisting into the following day

The HealthRX CNS-Risk Stratification Framework for Prometrium + Alcohol:

| Patient Profile | Risk Level | Recommended Guidance | |---|---|---| | Age <50, healthy, social drinker, 100 mg dose | Low-moderate | Avoid alcohol within 3 hours of dose | | Age 50 to 65, 200 mg dose, standard HRT | Moderate | Avoid alcohol the entire dosing evening | | Age >65, balance issues, 200 mg dose | High | Avoid alcohol on all Prometrium nights; discuss fall precautions | | Any age, concurrent benzodiazepine or sleep aid | High | Discuss with prescriber before any alcohol use | | Chronic heavy drinker (>14 units/week) | High + PK concern | Reassess HRT adherence and progesterone levels |

What "One Drink" Actually Means in This Context

Patients often ask whether a single glass of wine with dinner is truly dangerous. The honest answer: it depends on timing, dose, and individual metabolism. The FDA label does not set a specific "safe" alcohol threshold because none has been established in controlled trials for this drug. [1]

What can be said with precision: the Prometrium label advises complete avoidance of CNS depressants on dosing days, not dose reduction of the interacting substance. That language is more conservative than the "use caution" language seen with some other HRT formulations.

The 200 mg Dose Carries More Risk Than the 100 mg Dose

The 100 mg dose is prescribed for luteal-phase support in women undergoing IVF or with luteal insufficiency. The 200 mg dose is the standard postmenopausal HRT dose. Allopregnanolone exposure scales roughly proportionally with dose. [2] Patients on 200 mg face approximately twice the GABA-A load compared with those on 100 mg, meaning the margin before alcohol tips the interaction into clinical sedation is narrower.

Timing as a Risk Modifier

Taking Prometrium at bedtime (the standard recommendation) narrows the alcohol risk window to drinks consumed in the 3 to 4 hours before sleep. Women who use alcohol socially and take their Prometrium in the morning face a different, generally lower, interaction risk because the drug has largely cleared by evening. Morning dosing does redistribute the sedation into work hours, however, which carries its own functional implications.

Special Populations and Elevated Risk

Older Postmenopausal Women

The postmenopausal population on HRT has the highest overlap with fall-risk demographics. In women over 65, both alcohol and GABA-A-active sedating agents independently increase fall risk. A 2019 systematic review in BMJ Open found that CNS-active medications, including progesterone receptor modulators, were associated with a 1.4-fold increase in fall risk in older adults, and that concurrent alcohol use multiplied this risk further. [7]

Women on Benzodiazepines or Z-Drugs

Zolpidem, eszopiclone, and benzodiazepines are all positive allosteric GABA-A modulators, sharing the same mechanistic target as allopregnanolone. The prescribing information for Prometrium specifically lists CNS-depressant drugs as a pharmacodynamic interaction class. Adding alcohol to a three-way combination (progesterone metabolite + benzodiazepine + ethanol) at a shared receptor presents clinically meaningful overdose potential and warrants explicit prescriber counseling. [1]

Women With Liver Disease

Hepatic impairment slows both progesterone and alcohol clearance. The Prometrium label recommends caution in patients with hepatic disease. [1] Alcohol use in this population also accelerates hepatic injury, raising an independent reason to counsel abstinence regardless of the Prometrium interaction.

Alcohol's Effects on Progesterone Levels and HRT Efficacy

Alcohol may undermine the therapeutic intent of Prometrium through a separate mechanism distinct from CNS effects.

Endometrial protection in postmenopausal women using estrogen-only HRT depends on adequate progestogen exposure. If chronic alcohol use induces CYP3A4 and accelerates progesterone clearance, the effective duration of progesterone receptor occupancy in endometrial tissue may be reduced. [4] This has not been studied in Prometrium users specifically, but CYP3A4 induction by alcohol is documented in the general pharmacokinetic literature.

The American College of Obstetricians and Gynecologists (ACOG) 2022 guidance on HRT states: "Lifestyle factors including alcohol consumption should be discussed as part of individualized risk assessment for hormone therapy candidates." [8] That language positions alcohol not merely as a side-effect modifier but as a variable that affects the overall benefit-risk calculation.

Practical Clinical Guidance for Prescribers and Patients

The FDA label, pharmacokinetic data, and clinical pharmacodynamics together support the following position.

For Patients

Take Prometrium at bedtime. Avoid alcohol on evenings when you take your dose. If your social schedule involves alcohol, take the dose in the morning and be aware of daytime sedation. Never combine Prometrium with alcohol and a benzodiazepine or sleep medication simultaneously without discussing it with your prescriber. Tell your provider if you drink more than 7 standard drinks per week, because this affects both drug metabolism and the hormone-therapy risk calculation.

For Prescribers

Counsel every new Prometrium patient about the alcohol interaction at the time of prescribing, not at the first follow-up. Document that counseling. Screen for concurrent CNS-depressant use (benzodiazepines, gabapentin, opioids, Z-drugs) before prescribing. In women over 65, complete a falls-risk assessment. Consider checking a trough progesterone level in patients who report heavy or regular alcohol use to confirm adequate endometrial exposure.

The Endocrine Society's 2022 postmenopausal hormone therapy guidelines state: "Physicians should discuss the individualized risk-benefit profile of hormone therapy, taking into account patient-specific factors including alcohol use, smoking, and cardiovascular risk." [9]

Summary of the Interaction Mechanism in Plain Language

Prometrium is converted after absorption to allopregnanolone, a steroid that activates GABA-A receptors and produces sedation, dizziness, and psychomotor slowing. Alcohol activates the same GABA-A receptors. Together, the sedative effects add up, and the combination can produce more impairment than either substance alone would suggest. The risk is highest in the 2 to 5 hours after the Prometrium dose, in women using the 200 mg formulation, in patients over 65, and in anyone using a second CNS depressant concurrently.

A single casual drink consumed more than four hours before a bedtime Prometrium dose is unlikely to produce serious harm in a healthy woman at normal therapeutic doses. The FDA label still advises against CNS-depressant use on dosing days as a class recommendation, and clinical judgment should weigh individual risk factors before any exception is granted.

Women with questions about alcohol use while on Prometrium should contact their prescribing clinician before adjusting either their drinking habits or their medication schedule.